Key Products: Orforglipron (Foundayo), is first oral GLP-1 receptor agonist developed by the company that can be taken at any time of day
Individuals are encouraged to consult healthcare providers for tailored recommendations based on their health conditions and circumstances.)
Also Read: Indias GLP1 moment is herethe weightloss drug wars begin Anshul Gupta of Avendus Capital frames the opportunity plainly
Hemodynamic stresses induce endothelial dysfunction and remodeling of pulmonary artery in experimental compensated heart failurePubMed
The negative health consequences of obesity include an increased risk of a wide spectrum of diseases including type 2 diabetes (T2DM), other cardiovascular disease risk factors (e.g., hypertension and dyslipidemia), cardiovascular disease, thromboembolic events, musculoskeletal disorders, fatty liver, chronic kidney disease, certain cancers, mental health disorders, as well as sleep apnea, limited mobility, and diminished quality of life [[6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16]]
Recent weight gain is the major risk factor for development of the condition and its occurrence is most commonly observed in women of reproductive age with obesity
